1 Classification and terminology

1.1 Definition

Systemic lupus erythematosus is a chronic autoimmune disorder in which loss of immune tolerance leads the body to attack its own tissues. The disease is characterized by inflammation, variable patterns of organ involvement, and a course that often alternates between worsening activity and relative quiescence. It is considered systemic because it can affect several organs at once rather than being confined to a single tissue.

1.2 Relation to lupus erythematosus

Lupus erythematosus is a broader term that includes systemic and primarily cutaneous forms of the disease. Systemic lupus erythematosus represents the form most associated with internal organ involvement, while other variants mainly affect the skin. The term “lupus” is commonly used in everyday speech to refer to the systemic disease, although it can also denote the wider family of related disorders.

1.3 Disease subtypes

Systemic lupus erythematosus is one member of a spectrum of lupus-related conditions. These subtypes differ in the tissues they primarily affect, the severity of systemic disease, and their associations with medications or maternal antibodies. Some patients have features that overlap more than one subtype.

1.3.1 Cutaneous lupus erythematosus

Cutaneous lupus erythematosus refers to lupus that predominantly affects the skin. Lesions may be localized or widespread, and some forms are associated with photosensitivity and scarring. Skin-limited disease may occur independently or alongside systemic lupus erythematosus.

1.3.2 Drug-induced lupus

Drug-induced lupus is a lupus-like syndrome triggered by exposure to certain medications. It often resembles systemic lupus in symptoms and laboratory findings, but it usually improves after the offending drug is discontinued. Compared with classic systemic lupus, it more often has a reversible course and may show a narrower pattern of organ involvement.

1.3.3 Neonatal lupus

Neonatal lupus is a temporary condition affecting newborns exposed to maternal autoantibodies during pregnancy. It can cause skin findings, blood abnormalities, and, in some cases, congenital heart block. The disorder is not the same as lifelong systemic lupus in the infant, although it reflects autoimmune activity in the mother.

2 Signs and symptoms

The clinical presentation of systemic lupus erythematosus is highly variable. Some individuals have mild manifestations limited to the skin and joints, while others develop severe multisystem disease. Symptoms may appear gradually or emerge abruptly during flares.

2.1 Constitutional symptoms

Common general symptoms include fatigue, low-grade fever, malaise, weight loss, and reduced exercise tolerance. These complaints are often nonspecific and may precede more distinctive signs of the disease. Persistent fatigue is one of the most frequent and disabling features.

2.2 Musculoskeletal manifestations

Joint pain and swelling are among the most common manifestations. The arthritis of systemic lupus erythematosus is often symmetric and may involve the hands, wrists, knees, and other peripheral joints. Tendon inflammation, muscle aches, and morning stiffness may also occur, although destructive joint damage is less typical than in some other inflammatory disorders.

2.3 Cutaneous manifestations

Skin involvement may include a malar rash, photosensitivity, oral ulcers, hair thinning, and other inflammatory lesions. The facial rash classically crosses the cheeks and bridge of the nose, though not all patients develop this pattern. Sun exposure can worsen skin symptoms and trigger flares in susceptible individuals.

2.4 Renal manifestations

Kidney disease may present with protein in the urine, blood in the urine, swelling, or rising creatinine levels. In some cases, lupus nephritis is clinically silent at first and is detected only through urine testing or blood work. Renal involvement is important because it can progress without obvious early symptoms.

2.5 Neurological manifestations

The nervous system may be affected through headaches, cognitive dysfunction, seizures, mood changes, or, less commonly, psychosis and stroke-like events. These manifestations are diverse and may arise from inflammation, vascular injury, or immune-mediated mechanisms. Distinguishing lupus-related symptoms from other causes can be challenging.

2.6 Cardiopulmonary manifestations

The heart and lungs may be involved through pericarditis, pleuritis, myocarditis, pulmonary inflammation, or vascular complications. Patients may experience chest pain, shortness of breath, cough, or reduced stamina. Some complications are directly inflammatory, while others result from long-term disease or treatment effects.

2.7 Hematologic manifestations

Blood cell abnormalities are common and may include anemia, leukopenia, and thrombocytopenia. These changes can contribute to fatigue, infection risk, or bleeding tendencies. They may reflect immune-mediated destruction, bone marrow suppression, or inflammation-related shifts in blood production.

3 Causes and risk factors

The exact cause of systemic lupus erythematosus is not fully understood. Current evidence suggests that the disease results from an interaction between inherited susceptibility, environmental exposures, hormonal influences, and immune dysregulation.

3.1 Genetic susceptibility

Family clustering and twin studies indicate a hereditary component. Multiple genes contribute modestly to risk, particularly those involved in immune regulation and clearance of cellular debris. Genetic predisposition does not by itself cause disease, but it increases vulnerability when combined with other factors.

3.2 Environmental triggers

Environmental influences can contribute to disease onset or flares. Ultraviolet light is a well-known trigger, especially for skin symptoms. Infections, physical stress, and certain exposures may also influence immune activity in susceptible individuals.

3.3 Hormonal influences

Systemic lupus erythematosus occurs more often in females, especially during the reproductive years, suggesting a hormonal role. Estrogen and related biologic pathways are thought to affect immune responses. Hormonal influences help explain, in part, the age and sex distribution of the disease.

Some drugs can induce lupus-like syndromes or unmask latent autoimmunity. In drug-induced lupus, medication exposure is the key precipitant, and the clinical pattern may differ from that of idiopathic systemic lupus erythematosus. Careful medication review is therefore part of the diagnostic process.

4 Pathophysiology

Systemic lupus erythematosus arises from abnormal immune activation directed against self-antigens. Defects in immune tolerance, clearance of apoptotic material, and regulation of inflammatory pathways contribute to chronic tissue injury.

4.1 Autoantibody formation

A hallmark of the disease is the production of autoantibodies against nuclear and other cellular components. These antibodies arise when immune tolerance fails and autoreactive B and T cells become active. Their presence helps support diagnosis and often reflects underlying immune activation.

4.2 Immune complex deposition

Autoantibodies can bind to their targets and form immune complexes that circulate or deposit in tissues. These complexes may accumulate in organs such as the kidneys, skin, joints, and blood vessels. Once deposited, they promote local inflammation and injury.

4.3 Complement activation

Immune complexes can activate the complement system, a cascade of proteins that amplifies inflammation and helps recruit immune cells. Ongoing complement consumption may reduce circulating complement levels in active disease. This process contributes to tissue damage and is often used as a marker of disease activity.

4.4 Inflammatory tissue injury

Inflammation driven by immune cells, cytokines, and complement can damage organ structures over time. The resulting injury varies by tissue, producing symptoms ranging from rash and arthritis to nephritis and serositis. Repeated inflammatory episodes may lead to chronic impairment.

5 Diagnosis

Diagnosis is based on the combination of symptoms, physical findings, laboratory results, and exclusion of alternative explanations. Because the disease can mimic many other conditions, longitudinal assessment is often necessary.

5.1 Clinical evaluation

A thorough history and examination are essential. Clinicians assess patterns of rash, joint symptoms, constitutional complaints, organ-specific signs, medication exposure, and family history. The fluctuating nature of symptoms often makes repeated evaluation valuable.

5.2 Laboratory tests

Laboratory studies help identify immune abnormalities and assess organ involvement. Common tests include autoantibody panels, complement measurements, blood counts, and kidney-related studies. Results are interpreted in the context of the whole clinical picture.

5.2.1 Antinuclear antibody testing

Antinuclear antibody testing is often used as an initial screening study. A positive result is common in systemic lupus erythematosus, though it is not specific, since it can occur in other autoimmune disorders and even in some healthy people. A negative test makes the diagnosis less likely, but does not absolutely exclude it in all situations.

5.2.2 Anti-dsDNA and anti-Smith antibodies

Anti-double-stranded DNA and anti-Smith antibodies are among the more specific serologic markers for systemic lupus erythematosus. Anti-dsDNA levels may also correlate with disease activity in some patients, especially with kidney involvement. Their presence supports the diagnosis when considered alongside clinical findings.

5.2.3 Complement levels

Complement proteins, especially C3 and C4, may be reduced during active disease due to consumption. Lower levels can suggest ongoing immune complex activity. Trends over time may be more informative than a single measurement.

5.2.4 Urinalysis and kidney assessment

Urinalysis is important for detecting proteinuria, hematuria, cellular casts, and other signs of renal involvement. Additional testing may include serum creatinine, urine protein quantification, and, when indicated, renal biopsy. These studies help identify lupus nephritis and monitor response to treatment.

5.3 Classification criteria

Classification criteria provide a structured way to identify patients with systemic lupus erythematosus for clinical studies and, in practice, can assist diagnostic reasoning. They combine clinical and immunologic features into weighted frameworks. Although useful, they do not replace clinical judgment.

5.4 Differential diagnosis

Many disorders can resemble systemic lupus erythematosus, including other connective tissue diseases, infections, vasculitides, and medication-related syndromes. Symptoms such as fatigue, fever, rash, and arthralgia are nonspecific and may occur in numerous conditions. The differential diagnosis is guided by pattern recognition and targeted testing.

6 Management

Treatment aims to control inflammation, prevent organ damage, reduce flare frequency, and minimize treatment toxicity. Management is individualized according to the organs involved, disease severity, and patient-specific risks.

6.1 General treatment principles

Care typically combines symptom control, organ protection, and long-term monitoring. Mild disease may be managed with relatively conservative therapy, while severe organ involvement requires stronger immunosuppression. Regular follow-up is important because disease activity can change over time.

6.2 Antimalarial therapy

Antimalarial drugs, especially hydroxychloroquine, are widely used in systemic lupus erythematosus. They can help reduce skin and joint symptoms, decrease flare frequency, and support overall disease control. Their long-term use is common because of their broad benefit and generally favorable safety profile when monitored appropriately.

6.3 Corticosteroids

Corticosteroids are effective for rapid suppression of inflammation. They are often used during flares or in more serious organ disease, then tapered when possible to limit side effects. Because prolonged use can cause significant complications, clinicians generally aim for the lowest effective dose.

6.4 Immunosuppressive drugs

Immunosuppressive agents are used when organ-threatening disease is present or when steroid-sparing therapy is needed. Common examples include medications that reduce lymphocyte activity or inhibit immune cell proliferation. Choice of agent depends on the affected organ, severity, and tolerance of treatment.

6.5 Biologic therapies

Biologic therapies target specific immune pathways involved in lupus activity. They are typically considered when conventional therapy is insufficient or poorly tolerated. These agents may be used as add-on treatment in selected patients with persistent disease.

6.6 Supportive care

Supportive care addresses complications, symptom burden, and prevention of treatment-related harm. It includes lifestyle measures, vaccination planning, monitoring for adverse effects, and management of comorbidities. Good supportive care can substantially improve quality of life.

6.6.1 Sun protection

Sun avoidance and photoprotection are important because ultraviolet exposure can provoke skin disease and systemic flares. Protective clothing, broad-spectrum sunscreen, and limiting direct sun exposure are commonly advised. These measures are especially relevant for photosensitive patients.

6.6.2 Bone health

Long-term corticosteroid use can weaken bone density. Preventive strategies may include adequate calcium and vitamin D intake, weight-bearing exercise, and assessment for osteoporosis risk. Bone health monitoring is an important part of chronic care.

6.6.3 Infection prevention

Immunosuppressive therapy and the disease itself can increase susceptibility to infection. Preventive measures include appropriate vaccination, prompt evaluation of febrile illness, and attention to medication-related immune suppression. Infection prevention is a routine concern during treatment.

7 Organ-specific complications

Certain manifestations are serious enough to be considered major organ-specific complications. These conditions often determine prognosis and require targeted evaluation and therapy.

7.1 Lupus nephritis

Lupus nephritis is inflammation of the kidneys caused by systemic lupus erythematosus. It ranges from mild urinary abnormalities to progressive renal failure. Because kidney disease may be clinically subtle, regular screening is essential.

7.1.1 Clinical presentation

Patients may develop proteinuria, hematuria, edema, hypertension, or declining kidney function. Some present only with abnormal laboratory findings. The severity of symptoms does not always reflect the degree of histologic injury.

7.1.2 Biopsy and staging

Kidney biopsy is often used to define the pattern and severity of renal involvement. Histologic classification helps guide treatment intensity and provides prognostic information. Staging also assists in distinguishing active inflammation from chronic scarring.

7.1.3 Treatment approaches

Treatment usually combines corticosteroids with an immunosuppressive regimen tailored to biopsy findings and clinical severity. The goal is to preserve renal function and achieve durable control of inflammation. Long-term monitoring is needed to track response and detect relapse.

7.2 Neuropsychiatric lupus

Neuropsychiatric lupus includes central and peripheral nervous system manifestations attributed to systemic lupus erythematosus. Presentations can involve seizures, mood changes, cognitive impairment, headache, or other neurologic deficits. Diagnosis can be complex because similar symptoms may arise from medications, metabolic disturbances, or unrelated neurologic disease.

7.3 Cardiac involvement

Cardiac manifestations may include inflammation of the pericardium, myocardium, or heart valves. Patients can experience chest pain, palpitations, or shortness of breath. Over time, cardiovascular disease risk may also be increased by chronic inflammation and treatment effects.

7.4 Pulmonary involvement

Lung complications include pleuritis, pleural effusion, interstitial inflammation, pulmonary hypertension, and less commonly severe alveolar disease. Symptoms often include dyspnea, cough, or pleuritic chest discomfort. Pulmonary disease may be acute or gradually progressive.

7.5 Hematologic complications

Hematologic complications include autoimmune hemolytic anemia, leukopenia, lymphopenia, and thrombocytopenia. These abnormalities can increase fatigue, infection risk, or bleeding tendency. In some cases, they are among the earliest clues to diagnosis.

8 Disease course and prognosis

The course of systemic lupus erythematosus varies considerably. Some patients remain mildly affected for years, while others develop recurrent flares or cumulative organ damage.

8.1 Flares and remission

Disease activity often fluctuates, with periods of symptom worsening followed by partial or complete remission. Flares may be triggered by ultraviolet exposure, infection, treatment interruption, or no clearly identifiable factor. Recognizing early signs of relapse can help reduce complications.

8.2 Long-term outcomes

Long-term outcomes depend on organ involvement, treatment response, and the degree of accumulated damage. Many patients live with a chronic but manageable illness when diagnosis and therapy are timely. Functional status may be affected by fatigue, pain, renal disease, or medication side effects.

8.3 Mortality and major causes of complications

Serious complications are most often related to major organ disease, infection, cardiovascular problems, or treatment toxicity. Outcomes have improved over time with earlier recognition and better therapy. Nonetheless, systemic lupus erythematosus remains a potentially serious chronic disease.

9 Epidemiology

The distribution of systemic lupus erythematosus varies by sex, age, ancestry, and geography. These patterns provide clues to susceptibility, although no single factor fully explains disease occurrence.

9.1 Age and sex distribution

The disease is more common in females than males and often begins during adolescence or early adulthood. It can occur at any age, including childhood and later adulthood. Female predominance suggests a role for sex-related biologic factors.

9.2 Geographic and ethnic variation

Differences in prevalence and severity have been reported among populations in different regions and among diverse ancestral groups. These differences likely reflect a combination of genetic background, environmental exposure, access to care, and other social and biologic influences. Patterns may vary across studies and settings.

9.3 Incidence and prevalence

Systemic lupus erythematosus is an uncommon but not rare disease. Its prevalence differs across countries and populations, and reported figures depend on diagnostic methods and study design. Improved recognition has likely increased detection in many settings.

10 History

The history of lupus reflects a gradual shift from a descriptive skin disorder to a recognized multisystem autoimmune disease. Advances in pathology, immunology, and serology transformed understanding and management.

10.1 Early descriptions

Early medical descriptions focused mainly on visible skin lesions, especially those resembling a wolf bite, which contributed to the name lupus. For many years, the disease was understood primarily as a dermatologic condition. Recognition of internal organ involvement came later.

10.2 Development of modern diagnosis

Modern diagnosis advanced with the identification of characteristic autoantibodies and the development of laboratory methods for detecting them. These discoveries allowed lupus to be classified more reliably as an autoimmune disorder. Clinical criteria later provided additional structure for diagnosis and research.

10.3 Advances in treatment

Treatment evolved from limited symptomatic care to the use of antimalarials, corticosteroids, immunosuppressive drugs, and biologic agents. Better supportive care and monitoring have improved outcomes. The overall trend has been toward more precise control of inflammation with fewer long-term harms.

11 Research and future directions

Current research focuses on improving disease characterization, refining treatment selection, and identifying patients at risk of severe outcomes. The goal is more effective therapy with less toxicity.

11.1 Biomarkers

Biomarker research seeks laboratory measures that reflect disease activity, predict flares, and distinguish disease subsets. Useful biomarkers could help guide monitoring and treatment decisions. Several candidates are under investigation, but no single marker fully captures the complexity of the disease.

11.2 Targeted therapies

Targeted therapies aim at specific immune pathways involved in autoimmunity and inflammation. These approaches are intended to provide more selective disease control than broad immunosuppression. Ongoing studies are evaluating safety, efficacy, and the best patient populations for each agent.

11.3 Personalized medicine

Personalized medicine seeks to tailor therapy based on clinical phenotype, serology, genetics, and organ involvement. This approach may improve response rates and reduce unnecessary exposure to medications. In lupus, individualized care is especially relevant because the disease is so heterogeneous.